31 results
8-K
CCCC
C4 Therapeutics Inc
8 Mar 24
Departure of Directors or Certain Officers
4:10pm
(the "Retention Period"), the option holder either: (i) is terminated by the Company for cause or resigns from the Company, except by reason of death
8-K
EX-99.1
CCCC
C4 Therapeutics Inc
11 Jan 24
Regulation FD Disclosure
7:05am
Activate Fully Differentiated T-cells Regulate Hematopoietic Stem Cell Differentiation Consequences of IKZF1/3 Degradation: MM and NHL Cell Death T
8-K
EX-99.1
CCCC
C4 Therapeutics Inc
12 Dec 23
Regulation FD Disclosure
4:28pm
Differentiation Consequences of IKZF1/3 Degradation: MM and NHL Cell Death T-cell Activation On-target Neutropenia CD8+ activated CD8+ MM and NHL Cells 10 … = 22) Ongoing, n (%) 3 (14%) Discontinued, n (%) Progressive disease, n(%) Physician decision, n(%) Withdrawal by patient, n(%) Death, n (%) Adverse
8-K
CCCC
C4 Therapeutics Inc
20 Nov 23
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
7:05am
thereafter until his successor has been duly elected and qualified or until his earlier death, removal or resignation.
In connection with his
8-K
lfcb2x3rhmuw4octgx
2 Aug 22
C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors
8:33am
8-K
EX-99.1
9i8ana679suvp1q
8 Apr 22
C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader
1:21pm
8-K
3ponxg s3
16 Mar 22
C4 Therapeutics Appoints Utpal Koppikar to Board of Directors
4:15pm
8-K
EX-99.2
9vo4zp 3fk
26 May 21
Regulation FD Disclosure
4:28pm
8-K
EX-99.1
t3rf0cchj2zuv4ijw
13 May 21
C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
4:22pm
8-K
cty3o8xh0prq c8r8l
11 Mar 21
C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results
4:10pm
8-K
EX-99.1
6rq89kfbbd
19 Nov 20
Regulation FD Disclosure
5:00pm
8-K
EX-3.1
owv xn5e501kom60x42b
6 Oct 20
Departure of Directors or Certain Officers
4:46pm
424B4
63e6i lkmwj
2 Oct 20
Prospectus supplement with pricing info
5:10pm
S-1/A
fbja8fbm
28 Sep 20
IPO registration (amended)
6:07am
S-1/A
EX-10.2
q0mhk4e2qrd8
28 Sep 20
IPO registration (amended)
6:07am
S-1/A
EX-10.3
b1616rg gydzl58z89x
28 Sep 20
IPO registration (amended)
6:07am
S-1
EX-3.5
gat0r6s dtoalgtkfa
10 Sep 20
IPO registration
5:26pm
S-1
EX-3.4
asoz 7h6v3e5
10 Sep 20
IPO registration
5:26pm
S-1
EX-10.7
31ncgw501ijskvr5ujx8
10 Sep 20
IPO registration
5:26pm